[go: up one dir, main page]

WO2005074497A3 - Encapsulation vesicles enclosing self assembling activation agents - Google Patents

Encapsulation vesicles enclosing self assembling activation agents Download PDF

Info

Publication number
WO2005074497A3
WO2005074497A3 PCT/US2005/001927 US2005001927W WO2005074497A3 WO 2005074497 A3 WO2005074497 A3 WO 2005074497A3 US 2005001927 W US2005001927 W US 2005001927W WO 2005074497 A3 WO2005074497 A3 WO 2005074497A3
Authority
WO
WIPO (PCT)
Prior art keywords
self assembling
activation agents
encapsulation
encapsulation vesicles
vesicles enclosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/001927
Other languages
French (fr)
Other versions
WO2005074497A2 (en
Inventor
Timothy H Joyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemolytics Inc
Original Assignee
Hemolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemolytics Inc filed Critical Hemolytics Inc
Publication of WO2005074497A2 publication Critical patent/WO2005074497A2/en
Publication of WO2005074497A3 publication Critical patent/WO2005074497A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a composition and method for therapeutic treatment of humans and other mammals. The therapeutic composition of the present invention includes an encapsulation vesicle and an activation agent such as an α-DL peptide enclosed in the encapsulation vesicle. The activation agent may be in active or inactive form. A method of therapeutic treatment is also disclosed.
PCT/US2005/001927 2004-01-30 2005-01-21 Encapsulation vesicles enclosing self assembling activation agents Ceased WO2005074497A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76823504A 2004-01-30 2004-01-30
US10/768,235 2004-01-30

Publications (2)

Publication Number Publication Date
WO2005074497A2 WO2005074497A2 (en) 2005-08-18
WO2005074497A3 true WO2005074497A3 (en) 2006-04-27

Family

ID=34837793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001927 Ceased WO2005074497A2 (en) 2004-01-30 2005-01-21 Encapsulation vesicles enclosing self assembling activation agents

Country Status (1)

Country Link
WO (1) WO2005074497A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842749B2 (en) * 2012-06-12 2020-11-24 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
US11994484B2 (en) * 2021-03-25 2024-05-28 The Regents Of The University Of California Apparatus and method for single cell discrimination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents

Also Published As

Publication number Publication date
WO2005074497A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
EP1648406A4 (en) Uses and formulations for transdermal or transmucosal application of active agents
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004010952A3 (en) Methods and compositions for treatment of dermal conditions
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
ATE286718T1 (en) TEMPERATURE SENSITIVE LIPOSOMAL FORMULATION
WO2002094210A3 (en) Cosmetic agents
AU1261501A (en) Compositions and methods for intranasal delivery of active agents to the brain
AU2002321199A1 (en) Transdermal therapeutic system (TTS) with fentanyl as active ingredient
WO2004071538A3 (en) Topical delivery of cosmetic agents
DE60233891D1 (en) SELECTIVE TARGETING OF APOPTOTIC CELLS
WO2003020200A8 (en) A novel pharmaceutical compound and methods of making and using same
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2002036129A3 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2005094265A3 (en) Self assembling activation agents targeted using active drug release
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
WO2005074497A3 (en) Encapsulation vesicles enclosing self assembling activation agents
AU2003267360A1 (en) Hair treatment agent containing an active combination of liposomes
AU2002328402A1 (en) Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
EP1368003A4 (en) Methods and compositions for reducing the taste of pharmaceutically active agents
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2005069750A3 (en) Therapeutic composition with nanoscale activation agents
AU2003266607A1 (en) Therapeutic agent for rheumatism containing benzamide derivative as active ingredient
WO2002080940A3 (en) Pharmacologically active strong acid solutions
WO2003000700A3 (en) Ascorbyl derivatives of carnitines and cosmetic compositions containing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase